The Cosmetic Hedge Most Practices Misprice

The market-size number most owners use to justify a cosmetic line is a global figure wearing a US label. MarketsandMarkets publishes a US-specific medical aesthetics report putting the market at $9.46 billion in 2026 and $17.45 billion by 2031, a 13.0% CAGR. The figure circulating in trade press and LinkedIn decks is the same firm's global number, $22.59 billion to $40.60 billion. Same publisher, same methodology, entirely different addressable market.

The hedge itself is real, and it works at scale. Across Clarity's client base, cosmetic and self-pay runs about 18% of collections, $106 million of $589 million, which sits inside the band M&A advisors call the valuation sweet spot. Owners have good reason to reach for it: HFMA puts the dermatology impact of CMS's CY2027 proposed rule near negative 9%, and we ran that math in Why Derm's 9% Cut Won't Shrink to 3% This Year. What owners underprice is the cost of running the line, and it goes wrong in three predictable places.

Estimates of "the US aesthetics market" swing 3x to 15x on scope nobody discloses. Statifacts sizes US injectable aesthetics at $3.2 billion. Precedence Research sizes US aesthetic medicine at $25.47 billion. One counts syringes. The other counts everything short of the OR. Supply is easier to pin down: industry trackers count roughly 11,000 to 12,000 US medspas, with 800 to 1,200 net new locations a year concentrated in metros. Penetration is still single digit and demand is growing nearly as fast as supply, so the crowding is a metro problem. Count the injector chairs in your draw radius before a national TAM does any work in your model.

Industry pricing guides put neurotoxin gross margin at 60% to 75%, and ASPS pegs the national average filler retail price near $715 per syringe against wholesale of $150 to $300. That's a 3x to 4x markup on the invoice, and owners read it as the business margin.

Then the stack loads. A filler visit runs 15 to 30 minutes of procedure time but 45 to 90 minutes of chair time once consultation, consent, mapping, and post-care are counted, and that chair time carries injector compensation, a room, and front-desk labor. Labor and overhead absorb an estimated 25% to 45% of revenue.

FTI Consulting puts dermatology enterprise operating margins at 24.9% to 27.1%, though that's whole-practice, not cosmetic-line specific, and a medspa benchmark models about 22% net at median medspa revenue. Nothing in that set proves a cosmetic-specific number, so distrust anyone selling you one. The gap between 70% on the invoice and the low-to-mid 20s in the P&L is the whole mispricing.

Cash pay genuinely deletes the payer stack. Payment lands at the counter, in full, on the day of service, against a medical net collection rate that runs 95% or better in a well-run practice.

What replaces it is a demand-generation and retention cost the medical side never carried. Vendor benchmarks for aesthetic acquisition cost disagree by 3x to 10x, from a $68 median to bands of $100 to $350. Nobody can tell you what a new aesthetic patient costs. Medical derm patients arrive through referral networks at near-zero marginal cost, while cosmetic patients get bought, every time, and then re-earned.

One booking-platform analysis found 37% of injectable patients cancel their first rebooking, falling to 4% by the third visit. The standard fix is a membership program, which works and costs you: a worked Botox example shows gross margin compressing from roughly 79% to about 50% once the discount and banked units are priced in, and Allē and ASPIRE stack cost on top of that.

No-shows are the counterintuitive part. We've written before about why patient no-shows are skyrocketing on the medical side. The same booking-platform data puts cosmetic no-shows around 4% where deposits are in place. Frequency is not the risk. An empty cosmetic slot is a pure-zero loss with no payer backstop, and it lands hardest on first-time patients, the exact cohort your marketing dollars just bought.

ROI models for aesthetic devices show a $170,000 laser paying back in roughly 15 to 16 months at 35 treatments a month, and around 47 months at 20. Same device, same financing, only utilization moved. The same models put room occupancy above 55% as the point where the math starts working. Injectable-only additions break even fast on almost no fixed cost, which is why device-heavy buildouts are where failures concentrate.

Turnover is the second mode. Staffing guides for independent practices put RN injector turnover at 25% to 40% a year, with an estimated 30% to 50% of that injector's book leaving alongside them. Build the breakeven model on one injector's production and you've built it on one person's employment decision: if that injector leaves, the model resets and so does the payback clock.

One dermatology M&A guide puts 30% to 40% cosmetic revenue at the valuation sweet spot, with below 15% to 20% leaving margin on the table. Above 50%, benchmarking databases reclassify you as a medical aesthetic business, and one advisory playbook puts the repricing at 6x to 8x EBITDA versus 10x to 12x. We covered what buyers underwrite in The Dermatologist's Guide to a Defensible Valuation.

Clarity RCM manages revenue cycle for 200+ dermatology practices across 42 states. It's all we do. See how we work.